The House Energy and Commerce Health Subcommittee today held a hearing on implementation of the Compounding Quality Act, which updated federal requirements for drug compounding facilities after a 2012 fungal meningitis outbreak that was associated with a contaminated compounded steroid medication distributed to patients and providers in 23 states. Witnesses at the hearing included Food and Drug Administration Commissioner Scott Gottlieb, M.D.; officials from two companies that manufacture compounded sterile drugs; a patient; and representatives from the American Academy of Dermatology, International Academy of Compounding Pharmacists, The Pew Charitable Trusts, National Community Pharmacists Association, and American Academy of Ophthalmology. As FDA continues to implement the law, Gottlieb said the agency “plans to take steps that preserve lawful pharmacy practices and expand the opportunities for pharmacies that want to engage in larger-scale compounding to efficiently become 503B facilities.”

Related News Articles

Headline
The AHA yesterday voiced support for the Competitive Health Insurance Reform Act (H.R. 1418/S. 350), legislation that would repeal the antitrust exemption…
Headline
The AHA today voiced support for the Improving Seniors’ Timely Access to Care Act (H.R. 3107), bipartisan legislation that would establish requirements for the…
Headline
The House of Representatives today passed and sent to the President a Medicaid-related bill (H.R. 3253) that includes a provision extending the Certified…
Headline
Medicaid disproportionate share hospital payments to eligible hospitals covered 51% of their uncompensated care costs in 2014, the most recently available…
Headline
The House of Representatives today passed 284-149 a two-year budget agreement (H.R. 3877) that increases discretionary funding limits and suspends the debt…
Headline
Senate Finance Committee Chairman Chuck Grassley, R-Iowa, and Ranking Member Ron Wyden, D-Ore., today released a description of the chairman’s mark, the…